- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT03938792
Исследование эффективности и безопасности PF-06741086 у взрослых и подростков с тяжелой формой гемофилии А или от умеренно тяжелой до тяжелой гемофилии В
Открытое исследование у подростков и взрослых в тяжелой форме (активность фактора свертывания крови).
Обзор исследования
Тип исследования
Регистрация (Действительный)
Фаза
- Фаза 3
Контакты и местонахождение
Места учебы
-
-
-
Sofia, Болгария, 1756
- National Specialized Hospital for the Active Treatment of Hematological Diseases - EAD, Sofia
-
Stara Zagora, Болгария, 6003
- UMHAT "Prof.Dr. Stoyan Kirkovich"
-
-
-
-
-
Hong Kong, Гонконг
- Queen Mary Hospital
-
Hong Kong, Гонконг
- Prince of Wales Hospital
-
-
-
-
Gujarat
-
Surat, Gujarat, Индия, 395002
- Nirmal Hospital Pvt, Ltd
-
-
Maharashtra
-
Pune, Maharashtra, Индия, 411004
- Sahyadri Super Speciality Hospital
-
Pune, Maharashtra, Индия, 411004
- Sahyadri Clinical Research And Development Center
-
-
Tamil Nadu
-
Vellore, Tamil Nadu, Индия, 632004
- Christian Medical College
-
-
-
-
-
A Coruña, Испания, 15006
- Hospital Universitario A Coruna
-
Barcelona, Испания, 08035
- Hospital Universitario Vall d´Hebron
-
Madrid, Испания, 28046
- Hospital Universitario La Paz
-
Salamanca, Испания, 37007
- Hospital Universitario De Salamanca
-
Zaragoza, Испания, 50009
- Hospital Universitario Miguel Servet
-
-
-
-
-
Perugia, Италия, 06156
- Università degli Studi di Perugia, Azienda Ospedaliera di Perugia, Ospedale Santa Maria della
-
-
Milan
-
Milan, Milan, Италия, 20122
- Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
-
-
RM
-
Roma, RM, Италия, 00161
- Università degli Studi di Roma "Sapienza"-Policlinico Umberto I
-
-
-
-
Ontario
-
Hamilton, Ontario, Канада, L8S 4K1
- McMaster University
-
Hamilton, Ontario, Канада, L8S 4K1
- McMaster Children's Hospital
-
Hamilton, Ontario, Канада, L8N 3Z5
- McMaster University Medical Centre - Hamilton Health Sciences
-
Toronto, Ontario, Канада, M5G 1X8
- The Hospital for Sick Children
-
-
-
-
-
Beijing, Китай, 100045
- Beijing Children's Hospital, Capital Medical University
-
-
Guangdong
-
Guangzhou, Guangdong, Китай, 510515
- Nanfang Hospital, Southern Medical University
-
-
Guizhou
-
Guiyang, Guizhou, Китай, 550004
- The Affiliated Hospital of Guizhou Medical University
-
-
Jiangxi
-
Nanchang, Jiangxi, Китай, 306113
- Jiangxi Provincial People's Hospital
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Китай, 300020
- Institute of Hematology, Chinese Academy of Medical Sciences
-
-
-
-
Nuevo León
-
Monterrey, Nuevo León, Мексика, 64460
- Hospital Universitario "Dr Jose Eleuterio Gonzalez"
-
-
Yucatán
-
Mérida, Yucatán, Мексика, 97130
- Centro Multidisciplinario para el Desarrollo Especializado de la Inv. Clínica en Yucatán, S.C.P.
-
-
-
-
-
Muscat, Оман, 123
- Sultan Qaboos University Hospital
-
-
-
-
-
Samara, Россия, 443079
- FGBOU VO "Samara State Medical University" of MoH of Russia
-
-
-
-
-
Jeddah, Саудовская Аравия, 21589
- King AbdulAziz University Hospital
-
Riyadh, Саудовская Аравия
- King Faisal Specialist Hospital & Research Center
-
-
-
-
-
Belgrade, Сербия, 11000
- Clinical Center of Serbia
-
Belgrade, Сербия, 11000
- Institute for Mother and Child healthcare "Dr Vukan Cupic"
-
Kragujevac, Сербия, 34000
- Clinical Center Kragujevac
-
Niš, Сербия, 18000
- Clinical Center Niš
-
-
-
-
Florida
-
Tampa, Florida, Соединенные Штаты, 33612
- USF Health Morsani Center for Advanced Healthcare
-
-
Iowa
-
Iowa City, Iowa, Соединенные Штаты, 52242
- University of Iowa
-
-
New York
-
New Hyde Park, New York, Соединенные Штаты, 11040
- Northwell Health HTC
-
-
Washington
-
Seattle, Washington, Соединенные Штаты, 98101
- Washington Institute for Coagulation
-
-
-
-
-
Taichung, Тайвань, 40705
- Taichung Veterans General Hospital
-
-
Changhua County
-
Changhua, Changhua County, Тайвань, 500
- Changhua Christian Hospital
-
-
-
-
-
Adana, Турция (Туркие), 01130
- Acibadem Adana Hospital
-
Ankara, Турция (Туркие), 06230
- Hacettepe University Medical Faculty
-
Ankara, Турция (Туркие), 06500
- Gazi University Health Research and Practice Center Gazi Hospital
-
Antalya, Турция (Туркие), 07060
- Akdeniz University Medical Faculty
-
Gaziantep, Турция (Туркие), 27310
- Gaziantep University Sahinbey Research and Training Hospital
-
Istanbul, Турция (Туркие), 34093
- Istanbul University Oncology Institute
-
Izmir, Турция (Туркие), 35040
- Ege University Medical Faculty
-
Izmir, Турция (Туркие), 35210
- Dr. Behcet Uz Child Diseases Surgery Education and Research Hospital
-
Kayseri, Турция (Туркие), 38039
- Erciyes University Medical Faculty
-
Samsun, Турция (Туркие), 55280
- Ondokuz Mayıs University Medical Faculty
-
Trabzon, Турция (Туркие), 61080
- Karadeniz Technical University Medical Faculty
-
-
-
-
-
Paris, Франция, 75015
- Hôpital Necker Enfants malades
-
-
-
-
-
Zagreb, Хорватия, 10000
- Klinicki bolnicki centar Zagreb
-
-
-
-
Gauteng
-
Johannesburg, Gauteng, Южная Африка, 2193
- Charlotte Maxeke Johannesburg Academic Hospital
-
-
-
-
-
Daegu, Южная Корея, 41944
- Kyungpook National University Hospital
-
Seoul, Южная Корея, 03722
- Severance Hospital, Yonsei University Health System
-
Seoul, Южная Корея, 05278
- Kyung Hee University Hospital at Gangdong
-
-
-
-
-
Hiroshima, Япония, 734-8551
- Hiroshima University Hospital
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Япония, 466-8560
- Nagoya University Hospital - Transfusion Medicine
-
-
Hokkaido
-
Sapporo, Hokkaido, Япония, 004-0041
- Sapporo Tokushukai Hospital
-
-
Saitama
-
Iruma-gun, Saitama, Япония, 350-0495
- Saitama Medical University Hospital
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Описание
Критерии включения
- Участники с диагнозом тяжелой гемофилии А или умеренно тяжелой или тяжелой гемофилии с минимальным весом 35 кг при скрининге.
- Участник или законно уполномоченный представитель, или опекун участника, способный дать подписанное информированное согласие (или незначительное согласие, когда это применимо).
Участники, зачисленные в когорту без ингибиторов, также должны соответствовать следующим критериям:
- Отсутствие обнаруживаемой или задокументированной истории ингибиторов
- Участники, получающие рутинную профилактику FVIII/FIX, которые продемонстрировали не менее 80% соблюдения запланированного режима профилактики в течение 6 месяцев до включения в исследование и готовы продолжать получать рутинную профилактическую терапию с заменой FVIII/FIX во время фазы наблюдения.
- Участники с режимом лечения по требованию с ≥6 эпизодами острого кровотечения (спонтанного или травматического), которые требовали инфузии фактора свертывания крови в течение 6 месяцев до включения и желающие продолжать получать лечение по требованию во время фазы наблюдения.
Участники, зачисленные в когорту ингибиторов, также должны соответствовать следующим критериям:
- Документация по текущему ингибитору с высоким титром (≥5 БЕ/мл) или текущему ингибитору с низким титром (<5 БЕ/мл), рефрактерному к замене FVIII или FIX и с восстановлением FVIII или FIX <60% от ожидаемого в течение предыдущих 6 месяцев до включения в исследование. фаза наблюдения
- Участники гемофилии А с режимом лечения по требованию с ≥6 эпизодами кровотечения или участники гемофилии В с ≥4 эпизодами кровотечения (спонтанного или травматического), требующие лечения с помощью фактора шунтирования в течение 6 месяцев до включения в фазу наблюдения и желающие продолжать получать на - требовать лечения на этапе наблюдения.
- Участники, у которых задокументированы ингибиторы во время заместительной терапии, но которые не соответствуют количественным критериям ингибиторов, описанным в предыдущем пункте во время скрининга (например, участник с ранее задокументированным высоким титром ингибитора (≥5 BU/мл) и чье состояние исключает повторную провокацию с заменой FVIII или FIX) может рассматриваться на предмет приемлемости в каждом конкретном случае с предварительного согласия Pfizer Medical Monitor.
- Участники, которые соответствуют критериям кровотечения, указанным выше, и которые проходят обычную профилактику (определяемую как лечение путем внутривенной инъекции фактора шунтирования для предотвращения кровотечения) и продемонстрировали не менее 80% соблюдения запланированного режима профилактики в течение 6 месяцев до регистрации, могут быть рассматривается на предмет приемлемости в каждом конкретном случае при обсуждении и согласовании с медицинским наблюдателем Pfizer.
Критерий исключения
- Предшествующее или текущее лечение и/или история болезни коронарных артерий, венозного или артериального тромбоза или ишемической болезни
- Известная запланированная хирургическая процедура в течение запланированного периода исследования.
- Известный гемостатический дефект, отличный от гемофилии А или В.
- Нарушение функции почек или печени
- Текущее нестабильное заболевание печени или желчевыводящих путей
- Аномальные гематологические параметры
- Другое острое или хроническое медицинское или психиатрическое состояние или отклонения лабораторных показателей, которые могут увеличить риск, связанный с участием в исследовании или применением исследуемого продукта, или могут помешать интерпретации результатов исследования и, по мнению исследователя,
- Текущая рутинная профилактика шунтирующим агентом или некоагулянтной заместительной терапией, или любое предыдущее лечение продуктом генной терапии для лечения гемофилии (участники, получавшие профилактику с использованием шунтирующих агентов или ранее лечившиеся нефакторными препаратами, могут быть рассматривается в индивидуальном порядке).
Регулярная, сопутствующая терапия иммуномодулирующими препаратами
- Текущее или запланированное использование индукции иммунной толерантности во время фазы наблюдения или фазы активного лечения или профилактика заменой FVIII или FIX в любое время после начала лечения с помощью исследовательского вмешательства во время фазы активного лечения.
- Предыдущее воздействие PF 06741086 во время участия в исследованиях B7841002 и B7841003.
- Участие в других исследованиях с использованием исследуемых препаратов или исследуемых вакцин в течение 30 дней (или в соответствии с местными требованиями) или 5 периодов полувыведения до включения в исследование и/или во время участия в нем.
- Количество клеток CD4 ≤200/мкл, если вирус иммунодефицита человека (ВИЧ) положительный
- Скрининговая ЭКГ, демонстрирующая клинически значимые отклонения, которые могут повлиять на безопасность участников или интерпретацию результатов исследования.
- Лица с повышенной чувствительностью или аллергической реакцией на хомячий белок или другие компоненты исследуемого вмешательства.
- Сотрудники исследовательского центра, непосредственно участвующие в проведении исследования, и члены их семей, сотрудники исследовательского центра, иным образом контролируемые исследователем, или участники, являющиеся сотрудниками Pfizer, включая членов их семей, непосредственно участвующие в проведении исследования.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Н/Д
- Интервенционная модель: Назначение кроссовера
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: ПФ-06741086
Участникам будет назначено лечение с помощью PF-06741086 после 6-месячной фазы наблюдения за их текущим режимом лечения гемофилии.
|
300 миллиграммов (мг) подкожно (п/к) нагрузочная доза, а затем 150 мг кв один раз в неделю (qw).
300 мг подкожно один раз в неделю назначают участникам, которые соответствуют критериям повышения дозы.
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Model-Based Annualized Bleeding Rate (ABR) of Treated Bleeding Events: Inhibitor Cohort (Participants With Prior OD Therapy at OP)
Временное ограничение: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
ABR is defined as number of bleeding episodes per year.
ABR was calculated as number of bleeds requiring treatments/ (days on treatment period/365.25).
If a participant did not complete a treatment period, days on treatment ended at last dosing date + 6 days.
Treated bleed: If a bleed was treated with factor replacement or bypass agents within 48 hours of start of bleeding, regardless of the type of treatment (preventive, prophylaxis or OD medication).
A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
|
Model-Based ABR of Treated Bleeding Events: Non-Inhibitor Cohort (Participants With Prior OD Therapy at OP)
Временное ограничение: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
ABR is defined as number of bleeding episodes per year.
ABR was calculated as number of bleeds requiring treatments/ (days on treatment period/365.25).
If a participant did not complete a treatment period, days on treatment ended at last dosing date + 6 days.
Treated bleed: If a bleed was treated with factor replacement or bypass agents within 48 hours of start of bleeding, regardless of the type of treatment (preventive, prophylaxis or OD medication).
A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
|
Model-Based ABR of Treated Bleeding Events: Non-Inhibitor Cohort (Participants With RP at OP)
Временное ограничение: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
ABR is defined as number of bleeding episodes per year.
ABR was calculated as number of bleeds requiring treatments/ (days on treatment period/365.25).
If a participant did not complete a treatment period, days on treatment ended at last dosing date + 6 days.
Treated bleed: If a bleed was treated with factor replacement or bypass agents within 48 hours of start of bleeding, regardless of the type of treatment (preventive, prophylaxis or OD medication).
A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
|
Number of Participants With Adverse Events (AEs): Inhibitor and Non-Inhibitor Cohort
Временное ограничение: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
AEs included both serious AEs and all other AEs.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
|
Number of Participants With Serious Adverse Events (SAEs): Inhibitor and Non-Inhibitor Cohort
Временное ограничение: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
AE: any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
SAE: any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; or that was considered as an important medical event.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
|
Number of Participants With Thrombotic Events: Inhibitor and Non-Inhibitor Cohort
Временное ограничение: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
Thrombotic events are when a blood clot (thrombus) forms in a blood vessel in the arm, leg, lung, or head and can be life-threatening.
A thrombus can occur in veins (venous thrombosis) or arteries (arterial thrombosis).
|
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
|
Number of Participants With Thrombotic Microangiopathy: Inhibitor and Non-Inhibitor Cohort
Временное ограничение: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
Thrombotic microangiopathy: pathological state where micro-vessels are occluded by platelet rich thrombi leading to thrombocytopenia (low platelets) and microangiopathic haemolytic anaemia (red blood cell destruction) and potential end organ damage.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
|
Number of Participants With Disseminated Intravascular Coagulation/ Consumption Coagulopathy: Inhibitor and Non-Inhibitor Cohort
Временное ограничение: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
Disseminated intravascular coagulation is characterized by widespread clotting in small blood vessels, and consumption of platelets and clotting factors by the clots, leading to bleeding.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
|
Number of Participants With Anti-drug Antibodies (ADA) and Neutralizing Antibodies (NAb) Against PF- 06741086: Inhibitor and Non-Inhibitor Cohort
Временное ограничение: During prophylaxis treatment in ATP (12 months)
|
ADA positive: A participant with >=1 treatment induced or treatment-boosted ADA response.
NAb positive: An ADA positive participant with >=1 treatment induced or treatment boosted NAb response.
|
During prophylaxis treatment in ATP (12 months)
|
|
Number of Participants With Transient and Persistent ADA and NAb Against PF-06741086: Inhibitor and Non-Inhibitor Cohort
Временное ограничение: During prophylaxis treatment in ATP (12 months)
|
Persistent ADA: participant with treatment-induced or treatment-boosted ADA detected at 2 or more times during treatment including any follow-up, where first and last ADA positive samples separated by >=16 weeks.
Transient ADA: treatment-induced or treatment-boosted ADA detected at only 1 time during treatment or follow-up.
Persistent NAb: NAb-positive participant with first and last positive NAb samples detected >=16 weeks posttreatment, irrespective of any negative samples in between.
Transient NAb: NAb-positive participant with (1) treatment-induced/treatment-boosted NAb sample detected at only 1 time posttreatment or (2) treatment-induced/treatment-boosted NAb samples detected at 2 or more times where first and last positive samples separated by <16 weeks, and participant's last sample was NAb or ADA negative.
|
During prophylaxis treatment in ATP (12 months)
|
|
Number of Participants With Injection Site Reactions (ISRs): Inhibitor and Non-Inhibitor Cohort
Временное ограничение: During prophylaxis treatment in ATP (12 months)
|
ISR included: injection site haematoma, injection site pain, injection site bruising, injection site erythema, injection site induration, injection site oedema, Injection site pruritus and Injection site swelling.
ISR graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 where grade 1: tenderness with or without associated symptoms (warmth, erythema, itching), grade 2: pain, lipodystrophy, edema, phlebitis, grade 3: ulceration or necrosis, severe tissue damage, operative intervention indicated, grade 4: life-threatening consequences, urgent intervention indicated and grade 5: death.
In this outcome measure only categories with non-zero values reported.
|
During prophylaxis treatment in ATP (12 months)
|
|
Number of Participants With Clinically Significant Changes in Physical Examinations: Inhibitor and Non-Inhibitor Cohort
Временное ограничение: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
Physical examination included assessments of the head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems.
Height and weight were also measured and recorded.
Clinical significance in physical examinations was determined by investigator.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
|
Number of Participants With Clinically Significant Changes in Vital Signs: Inhibitor and Non-Inhibitor Cohort
Временное ограничение: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
Vital signs included temperature, pulse rate, respiratory rate, and blood pressure.
Blood pressure and pulse rate were measured in a supine position using completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions.
Respiratory rate was measured by observing and counting the respirations of the participant for 30 seconds and multiplied by 2. Clinical significance of vital signs was determined by investigator.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
|
Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters: Inhibitor and Non-Inhibitor Cohort
Временное ограничение: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
Hematology included: hemoglobin; leukocytes; neutrophils; and platelets.
Chemistry included: potassium; aspartate aminotransferase; creatinine; alkaline phosphatase; total bilirubin; albumin; calcium corrected, estimated decreased; sodium; and calcium.
Clinical significance of laboratory parameters was determined by investigator.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
|
|
Number of Participants With Severe/ Systematic Hypersensitivity and Anaphylactic Reactions: Inhibitor and Non-Inhibitor Cohort
Временное ограничение: During prophylaxis treatment in ATP (12 months)
|
Systemic hypersensitivity is a complex immune response where the immune system reacts excessively to an antigen, often leading to severe allergic reactions, including widespread symptoms (which may affect multiple organs), such as rash, swelling of your face, lips, mouth, or tongue, trouble breathing, wheezing, dizziness, fainting, fast heartbeat, pounding in your chest or sweating.
Anaphylaxis is a severe, potentially fatal, systemic allergic reaction that occurs suddenly after contact with an allergy causing substance.
|
During prophylaxis treatment in ATP (12 months)
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Model-Based ABR of Joint Bleeds: Inhibitor and Non-Inhibitor Cohort
Временное ограничение: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
ABR: number of bleeding episodes per year.
ABR was calculated as number of bleeds requiring treatments/ (days on treatment period/365.25).
If a participant did not complete a treatment period, days on treatment ended at last dosing date + 6 days.
Joint bleed: bleeding episode characterized by rapid loss of range of motion as compared with baseline that was associated with any combination of the following: pain or an unusual sensation in the joint, palpable swelling, and warmth of the skin over the joint.
A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
|
Model-Based ABR of Spontaneous Bleeds: Inhibitor and Non-Inhibitor Cohort
Временное ограничение: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
ABR: number of bleeding episodes per year.
ABR was calculated as the number of bleeds requiring treatments/ (days on treatment period/365.25).
If a participant did not complete a treatment period, the days on treatment ended at the last dosing date + 6 days.
Spontaneous bleed: Bleeding for no apparent/known reason particularly into the joints, muscles, and soft tissues.
A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
|
Model-Based ABR of Target Joint Bleeds: Inhibitor and Non-Inhibitor Cohort
Временное ограничение: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
ABR: number of bleeding episodes per year.
ABR was calculated as number of bleeds requiring treatments/ (days on treatment period/365.25).
If participant did not complete a treatment period, days on treatment ended at last dosing date + 6 days.
Target joint: a major joint into which repeated bleeds occurred.
Joint bleed: bleeding episode characterized by rapid loss of range of motion as compared with baseline that was associated with any combination of following: pain or unusual sensation in joint, palpable swelling, and warmth of the skin over joint.
A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
|
Model-Based ABR of Total Bleeds: Inhibitor and Non-Inhibitor Cohort
Временное ограничение: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
ABR: number of bleeding episodes per year.
ABR was calculated as number of bleeds requiring treatments/ (days on treatment period/365.25).
If participant did not complete treatment period, days on treatment ended at last dosing date + 6 days.
Treated bleed: If a bleed was treated with factor replacement or bypass agents within 48 hours of start of bleeding, regardless of the type of treatment (preventive, prophylaxis or on-demand medication).
Untreated bleed: If a bleed was untreated with factor replacement or bypass agents within 48 hours of start of bleeding, regardless of the type of treatment (preventive, prophylaxis or on-demand medication), it was considered as an untreated bleed.
Total bleeds: Treated bleeds + untreated bleeds.
A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
|
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
|
|
Change From Baseline in Hemophilia Joint Health Score (HJHS) at Month 6: Non-Inhibitor Cohort
Временное ограничение: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
HJHS evaluated total joint score for 6 joints (left ankle, right ankle, left elbow, right elbow, left knee, right knee) and the global gait score.
Joint total score per joint ranged from 0 to 20 (evaluated as: swelling [0-3], duration of swelling [0-1], muscle atrophy [0-2], crepitus on motion [0-2], flexion loss [0-3], extension loss [0-3], joint pain [0-2], and strength [0-4]).
Global gait score ranged from 0 to 4 based on walking, stairs, running, and hopping on 1 leg.
HJHS total score was sum of total joint score for 6 joints (0 to 120) and global gait score (0 to 4).
The total HJHS score ranged from 0 to 124, where higher scores indicated worse joint health.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
|
Change From Baseline in HJHS at Month 6: Inhibitor Cohort
Временное ограничение: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
HJHS evaluated total joint score for 6 joints (left ankle, right ankle, left elbow, right elbow, left knee, right knee) and the global gait score.
Joint total score per joint ranged from 0 to 20 (evaluated as: swelling [0-3], duration of swelling [0-1], muscle atrophy [0-2], crepitus on motion [0-2], flexion loss [0-3], extension loss [0-3], joint pain [0-2], and strength [0-4]).
Global gait score ranged from 0 to 4 based on walking, stairs, running, and hopping on 1 leg.
HJHS total score was sum of total joint score for 6 joints (0 to 120) and global gait score (0 to 4).
The total HJHS score ranged from 0 to 124, where higher scores indicated worse joint health.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
|
Change From Baseline in Hemophilia Quality of Life Questionnaire for Adults (Haem-A-QoL) Total Score and Physical Health Domain at Month 6: Non-Inhibitor Cohort, Participants >=17 Years
Временное ограничение: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
Haem-A-QoL assessed health-related quality of life (QoL) in adult participants (>=17 years of age) with hemophilia.
It contained 46 items with 10 domains that assessed health in the following areas: physical health; feelings; view of self; sports and leisure; work and school; dealing with haemophilia; treatment; future; family planning; partnership and sexuality.
All items were based on a 5-point Likert type scale (1= never, 2= rarely, 3= sometimes, 4= often, 5= all the time).
Scoring was performed by averaging non-missing item responses for each domain, then each domain score was rescaled from 0 to 100, lower scores signified higher QoL.
Total Haem-A-QoL score was averaged across the 46 items values and then rescaled from 0 to 100, lower Haem-A-QoL scores signified better QoL.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
|
Change From Baseline in Haem-A-QoL Total Score and Physical Health Domain at Month 6: Inhibitor Cohort, Participants >=17 Years
Временное ограничение: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
Haem-A-QoL assessed health-related quality of life (QoL) in adult participants (>=17 years of age) with hemophilia.
It contained 46 items with 10 domains that assessed health in the following areas: physical health; feelings; view of self; sports and leisure; work and school; dealing with haemophilia; treatment; future; family planning; partnership and sexuality.
All items were based on a 5-point Likert type scale (1= never, 2= rarely, 3= sometimes, 4= often, 5= all the time).
Scoring was performed by averaging non-missing item responses for each domain, then each domain score was rescaled from 0 to 100, lower scores signified higher QoL.
Total Haem-A-QoL score was averaged across the 46 items values and then rescaled from 0 to 100, lower Haem-A-QoL scores signified better QoL.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
|
Change From Baseline in Hemophilia Quality of Life Questionnaire for Children (Haemo-QoL) Total Score at Month 6: Non-Inhibitor Cohort, Participants 12 to <17 Years
Временное ограничение: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
Haemo-QoL assessed health-related QoL in adolescent participants (12 to <17 years of age) with hemophilia.
It contains 12 items with 77 domains that assesses health in the following areas: physical health; feelings; attitude/view; family; friends; other people; sport and school; coping/dealing; treatment; perceived support; future and relationship.
All items were based on 5-point Likert type scale (1= never, 2= rarely, 3= sometimes, 4= often, 5= all the time).
Scoring was performed by averaging non-missing item responses for each domain, then rescaled from 0 to 100, lower scores signified higher QoL.
Total Haem-A QoL score was averaged across the 77 items values and then rescaled from 0 to 100, lower Haemo-QoL scores signified better QoL.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
|
Change From Baseline in Haemo-QoL Total Score at Month 6: Inhibitor Cohort, Participants 12 to <17 Years
Временное ограничение: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
Haemo-QoL assessed health-related QoL in adolescent participants (12 to <17 years of age) with hemophilia.
It contains 12 items with 77 domains that assesses health in the following areas: physical health; feelings; attitude/view; family; friends; other people; sport and school; coping/dealing; treatment; perceived support; future and relationship.
All items were based on 5-point Likert type scale (1= never, 2= rarely, 3= sometimes, 4= often, 5= all the time).
Scoring was performed by averaging non-missing item responses for each domain, then rescaled from 0 to 100, lower scores signified higher QoL.
Total Haem-A QoL score was averaged across the 77 items values and then rescaled from 0 to 100, lower Haemo-QoL scores signified better QoL.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
|
Change From Baseline in Hemophilia Activities List (HAL) Total Score at Month 6: Non-Inhibitor Cohort, Participants >=17 Years
Временное ограничение: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
The HAL was a multiple domain measure of the impact of hemophilia on functional abilities in adults (>=17 years of age).
The 7 domains of this instrument contained 42 items in total, as follows: lying/sitting/kneeling/standing; lower (leg) functioning; upper (arm) functioning; transportation; self-care; household tasks; and sports/leisure.
Items were rated on 6-point scale 1 (impossible) to 6 (never) that described difficulty due to hemophilia.
HAL total score was sum of all items and scored 42 to 252, which were transformed to 0 - 100, where higher scores indicated better functional status.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
|
Change From Baseline in HAL Total Score at Month 6: Inhibitor Cohort, Participants >=17 Years
Временное ограничение: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
The HAL was a multiple domain measure of the impact of hemophilia on functional abilities in adults (>=17 years of age).
The 7 domains of this instrument contained 42 items in total, as follows: lying/sitting/kneeling/standing; lower (leg) functioning; upper (arm) functioning; transportation; self-care; household tasks; and sports/leisure.
Items were rated on 6-point scale 1 (impossible) to 6 (never) that described difficulty due to hemophilia.
HAL total score was sum of all items and scored 42 to 252, which were transformed to 0 - 100, where higher scores indicated better functional status.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
|
Change From Baseline in Pediatric Hemophilia Activities List (pedHAL) Total Score at Month 6: Non-Inhibitor Cohort, Participants 12 to <17 Years
Временное ограничение: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
The pedHAL was a multiple domain measure of the impact of hemophilia on functional abilities in adolescents (12 to <17 years of age).
The 7 domains of this instrument contained 53 items in total, as follows: sitting/kneeling/standing; functions of the legs; functions of the arms; use of transportation; self-care; household tasks; leisure activities and sports.
Items were rated on 6-point scale 1 (impossible) to 6 (never) that described difficulty due to hemophilia.
pedHAL total score was normalized in a range of 0 - 100, where higher scores indicated better functional status.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
|
Change From Baseline in pedHAL Total Score at Month 6: Inhibitor Cohort, Participants 12 to <17 Years
Временное ограничение: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
The pedHAL was a multiple domain measure of the impact of hemophilia on functional abilities in adolescents (12 to <17 years of age).
The 7 domains of this instrument contained 53 items in total, as follows: sitting/kneeling/standing; functions of the legs; functions of the arms; use of transportation; self-care; household tasks; leisure activities and sports.
Items were rated on 6-point scale 1 (impossible) to 6 (never) that described difficulty due to hemophilia.
pedHAL total score was normalized in a range of 0 - 100, where higher scores indicated better functional status.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
|
Patient Global Impression of Change-Hemophilia (PGIC-H) at Month 6: Non-Inhibitor Cohort
Временное ограничение: Month 6
|
The PGIC-H was a single item assessment of the participant's overall impression of change in their life with hemophilia, on a 7-point scale (1= greatly improved to 7= greatly worsened, where lower scores indicated better improvement).
|
Month 6
|
|
PGIC-H at Month 6: Inhibitor Cohort
Временное ограничение: Month 6
|
The PGIC-H was a single item assessment of the participant's overall impression of change in their life with hemophilia, on a 7-point scale (1= greatly improved to 7= greatly worsened, where lower scores indicated better improvement).
|
Month 6
|
|
Change From Baseline in EuroQol 5 Dimensions 5 Level (EQ-5D-5L) Index and VAS Scores at Month 6: Non-Inhibitor Cohort
Временное ограничение: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
EQ-5D-5L consisted of participant completed questionnaire with 2 components: health state profile index and visual analogue scale (VAS).
EQ-5D health state profile index has 5 domains (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), with 5 levels (1= no problems, 2= slight problems, 3= moderate problems, 4= severe problems, 5= extreme problems).
Responses to 5 dimensions comprised health state index value.
E.g. if a participant responds "no problems" for each 5 dimensions, then health state was coded as "11111" with predefined index value to it.
EQ-5D-5L index score ranged from -0.594 to 1, United Kingdom look-up value was applied to all participants, higher scores indicated better health states.
The EQ- VAS measured participant's self-rated health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state) by VAS, where higher scores indicated better heath states.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
|
Change From Baseline in EQ-5D-5L Index and VAS Scores at Month 6: Inhibitor Cohort
Временное ограничение: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
EQ-5D-5L consisted of participant completed questionnaire with 2 components: health state profile index and visual analogue scale (VAS).
EQ-5D health state profile index has 5 domains (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), with 5 levels (1= no problems, 2= slight problems, 3= moderate problems, 4= severe problems, 5= extreme problems).
Responses to 5 dimensions comprised health state index value.
E.g. if a participant responds "no problems" for each 5 dimensions, then health state was coded as "11111" with predefined index value to it.
EQ-5D-5L index score ranged from -0.594 to 1, United Kingdom look-up value was applied to all participants, higher scores indicated better health states.
The EQ- VAS measured participant's self-rated health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state) by VAS, where higher scores indicated better heath states.
|
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
|
Соавторы и исследователи
Спонсор
Следователи
- Директор по исследованиям: Pfizer CT.gov Call Center, Pfizer
Публикации и полезные ссылки
Общие публикации
- Matino D, Acharya SS, Taylor CT, Sun P, Agathon D, Raje S, Gould T, Palladino A, Mahlangu J, Lissitchkov T, Todorova M, Chan A, Carcao M, Sun J, Yang R, Wu R, Jin C, Zeng X, Boban A, Bilic E, Frenzel L, Fung Chan GC, Kong Li C, Apte S, Choraria N, Chistolini A, Marchesini E, Peyvandi F, Fujii T, Matsushita T, Kaneda M, Lyu CJ, Park YS, Kim S, Martinez LV, Adrian JM, Wali Y, Al Khabori M, Kurtov I, Alzahrani H, Zaher G, Micic D, Miljic P, Kostic G, Vucic M, Djurdjevic P, Hidalgo OB, Porras JG, Jimenez-Yuste V, Calvo Villas JM, Lopez Fernandez MF, Albayrak C, Okan V, Balkan C, Sahin F, Antmen A, Unal E, Visweshwar N, Sharathkumar A, Kruse-Jarres R. Efficacy and safety of marstacimab prophylaxis in hemophilia A/B with inhibitors: results from the phase 3 BASIS trial. Blood. 2026 Feb 26;147(9):920-931. doi: 10.1182/blood.2025031065.
- Matino D, Palladino A, Taylor CT, Hwang E, Raje S, Nayak S, McDonald R, Acharya SS, Mahlangu J, Jimenez-Yuste V, Choraria N, Yang R, Li CK, Al-Khabori M, Wali Y, Morales Adrian J, Park YS, Zulfikar OB, Teeter J. Marstacimab prophylaxis in hemophilia A/B without inhibitors: results from the phase 3 BASIS trial. Blood. 2025 Oct 2;146(14):1654-1663. doi: 10.1182/blood.2024027468.
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Действительный)
Завершение исследования (Действительный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
- Патологические процессы
- Генетические заболевания, врожденные
- Гематологические заболевания
- Нарушения свертывания крови
- Геморрагические расстройства
- Генетические заболевания, сцепленные с Х-хромосомой
- Нарушения свертывания крови, наследственные
- Нарушения белковой коагуляции
- Врожденные, наследственные и неонатальные заболевания и аномалии
- Патологические состояния, признаки и симптомы
- Гемики и лимфатические заболевания
- Гемофилия А
- Кровотечение
- Гемофилия В
- Марстацимаб
Другие идентификационные номера исследования
- B7841005
- 2018-003660-31 (Номер EudraCT)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .